Alerts will be sent to your verified email
Verify EmailERIS
Eris Lifesciences
|
Pfizer
|
Astrazeneca Pharma I
|
|
---|---|---|---|
Operational Metrics
|
|||
Pharmaceutical Sector
|
|||
Domestic Sales Growth - YoY
|
9.3 % | 4.7 % | 18.6 % |
R&D as a % of Total Sales
|
0.0 | n/a | 0.0 |
Financials
|
|||
5 yr Average ROE
|
19.85 % | 18.39 % | 18.37 % |
5yr average Equity Multiplier
|
1.5 | 1.28 | 1.94 |
5yr Average Asset Turnover Ratio
|
0.58 | 0.6 | 0.94 |
5yr Avg Net Profit Margin
|
25.85 % | 24.04 % | 10.03 % |
Price to Book
|
7.23 | 5.18 | 33.37 |
P/E
|
60.83 | 31.54 | 233.79 |
5yr Avg Cash Conversion Cycle
|
-99.43 Days | -2.02 Days | -36.14 Days |
Inventory Days
|
26.22 Days | 49.44 Days | 64.11 Days |
Days Receivable
|
61.69 Days | 26.74 Days | 36.53 Days |
Days Payable
|
164.23 Days | 81.1 Days | 208.62 Days |
5yr Average Interest Coverage Ratio
|
94.87 | 170.95 | 140.96 |
5yr Avg ROCE
|
21.14 % | 23.56 % | 23.99 % |
5yr Avg Operating Profit Margin
|
34.25 % | 30.56 % | 14.51 % |
5 yr average Debt to Equity
|
0.29 | 0.0 | 0.0 |
5yr CAGR Net Profit
|
5.74 % | 65.36 % | 17.47 % |
5yr Average Return on Assets
|
15.49 % | 14.39 % | 9.52 % |
Shareholdings
|
|||
Promoter Holding
|
54.85 % | 63.92 % | 75.0 % |
Share Pledged by Promoters
|
18.51 % | 0.0 | 0.0 |
Change in Promoter Holding (3 Yrs)
|
2.19 % | 0.0 | 0.0 |
Change in Mutual Fund Holding (3 Yrs)
|
6.48 % | 3.65 % | 3.46 % |
Eris Lifesciences
|
Pfizer
|
Astrazeneca Pharma I
|
|
---|---|---|---|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Entity Wise Breakup
|
Entity Wise Breakup
|
-
|
-
|
EBITDA - Entity Wise
|
EBITDA - Entity Wise
|
-
|
-
|
Therapeutic Area Wise Break-Up - Domestic
|
Therapeutic Area Wise Break-Up - Domestic
|
-
|
-
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Acute vs Chronic
|
Acute vs Chronic
|
-
|
-
|